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BACKGROUND: Photodynamic therapy (PDT) is a treatment modality for a range of diseases including cancer. The BF2-chelated
tetraaryl-azadipyrromethenes (ADPMs) are an emerging class of non-porphyrin PDT agent, which have previously shown excellent
photochemical and photophysical properties for therapeutic application. Herein, in vivo efficacy and mechanism of action studies have
been completed for the lead agent, ADMP06.
METHODS: A multi-modality imaging approach was employed to assess efficacy of treatment, as well as probe the mechanism of action
of ADPM06-mediated PDT.
RESULTS: Tumour ablation in 71% of animals bearing mammary tumours was achieved after delivery of 2mgkg
 1 of ADPM06 followed
immediately by light irradiation with 150Jcm
 2. The inherent fluorescence of ADPM06 was utilised to monitor organ biodistribution
patterns, with fluorescence reaching baseline levels in all organs within 24h. Mechanism of action studies were carried out using dynamic
positron emission tomography and magnetic resonance imaging techniques, which, when taken together, indicated a decrease in tumour
vascular perfusion and concomitant reduction in tumour metabolism over time after treatment.
CONCLUSION: The encouraging treatment responses in vivo and vascular-targeting mechanism of action continue to indicate therapeutic
benefit for this new class of photosensitiser.
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Photodynamic therapy (PDT) is an emerging treatment modality
whereby a photosensitiser is administered systemically or locally
and subsequently activated by illumination with visible light,
leading to the generation of cytotoxic reactive oxygen species
(Palumbo, 2007). The interaction of photosensitiser and light
results in photochemical production of activated oxygen species,
from endogenous oxygen, which attack key structural entities
within the targeted cells. Photodynamic therapy is currently
used for the treatment of various types of cancer, including the
lung, skin, gastrointestinal tract, head and neck, and urological
cancers, as well as non-cancer diseases such as age-related macular
degeneration (AMD), atherosclerosis, and viral or bacterial infec-
tions (Kossodo and LaMuraglia, 2001; Hamblin and Hasan, 2004;
Wormald et al, 2007). The efficacy of PDT in the treatment of
cancer depends on photosensitiser concentration and localisation,
coupled with light dose (fluence), and oxygen availability. The singlet
oxygen generated by the photochemical reaction of photosensitiser
and light can directly kill tumour cells through the induction of
apoptosis and/or necrosis, or may damage the tumour vasculature
and healthy vessels, resulting in hypoxia and oxygen starvation, thus
causing indirect tumour kill (Triesscheijn et al, 2006). In addition,
PDT can initiate an immune response against the remaining tumour
cells. The outcome of PDT is dependent on all these mechanisms and
the relative contribution of each depends on the treatment regimen
employed (Triesscheijn et al, 2006).
To elicit a vascular-targeting effect, therapeutic effectors or
cytotoxic agents need to be selectively delivered to the tumour
vasculature (Chen et al, 2006). Passive targeting of the tumour
vessels while an i.v. injected agent is still within the vessel is
perhaps the most feasibly effective approach. During recent years,
vascular-targeted PDT has received much interest and select
vascular-targeting photosensitisers are already in clinical develop-
ment for PDT of AMD and certain cancers (Trachtenberg et al,
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s2007, 2008; Schmidt-Erfurth and Sacu, 2008). The relative
contributions of vascular-mediated vs direct tumour toxicity
depend on the sensitiser and on the interval between sensitiser
administration and illumination. For short intervals (i.e., irradia-
tion directly after drug administration), when there is a high drug
concentration in circulating plasma, the vascular damage is
maximised. For longer intervals, when the drug has been
distributed to tumour tissue, direct cell toxicity becomes more
important (Chen et al, 2006).
We have previously reported the discovery of a novel class of
non-porphyrin-based modifiable PDT agents, termed the BF2-
chelated tetraaryl-azadipyrromethenes (ADPMs), and have shown
in vitro that their photophysical and biological characteristics have
significant potential for the development as new anti-cancer
therapeutics (Gorman et al, 2004; Gallagher et al, 2005). We have
shown that this new class of PDT agent possesses excellent
photophysical properties and as having EC50 values in the low
nano-molar range for lead compound ADPM06, with no discern-
able activity bias for a specific tumour cell type. Moreover, these
novel photosensitisers show low to non-determinable dark
toxicity. Critically, the synthesis of these compounds is straight-
forward and results in defined single agents. This characteristic
places the ADPM genus in the category of being a family of pure
and modifiable molecular photosensitisers. Thus, the ADPMs are
discrete structures that are amenable to modification around the
periphery of the chromophore, thus allowing for optimisation of
all aspects of their photophysical and therapeutic properties.
In this study, we have used a short drug–light interval protocol
with lead compound ADPM06 to show tolerance and efficacy in
several animal models of cancer. We have also exploited the
inherent fluorescent properties of a candidate PDT agent to
directly assess in vivo drug biodistribution profiles using optical
imaging. Moreover, using positron emission tomography (PET) and
magnetic resonance imaging (MRI), we have also shown that our
current ADPM06 treatment regimen elicits a vascular-targeting effect.
MATERIALS AND METHODS
Photosensitiser
The synthesis and formulation of the ADPM family of compounds
in a mixture of Cremophor EL (CrEL)/1,2-propanediol (10:3 v/v)
has been described previously (Gorman et al, 2004). The quantity
of CrEL/1,2-propanediol in an assayed photosensitiser solution
was always o0.03%.
Cells
MDA-MB-231 tumour cells were obtained from the American Type
Culture Collection (ATCC) and cultured in minimum essential
medium supplemented with 10% (v/v) foetal calf serum, 1% (v/v)
non-essential amino acids, 50Uml
 1 penicillin, 50mgml
 1 strep-
tomycin, 1% (v/v) sodium pyruvate, and 1% (v/v) L-glutamine. All
cells were maintained in 5% CO2 (v/v) and 21% O2 (v/v) at 371C.
MDA-MB-231 luciferase-expressing cell line (MDA-MB-231-luc)
was obtained from Caliper LS (Alameda, CA, USA) and maintained
as above. Human umbilical vein endothelial cells (HUVECs) were
obtained from Clonetics (Basel, Switzerland) and maintained in
endothelial cell growth medium (EGM; Clonetics), containing
12mgml
 1 bovine brain extract, 10ngml
 1 EGF, 1mgml
 1 hydro-
cortisone, 50mgml
 1 gentamicin, 50ngml
 1 amphotericin B, and
2% foetal bovine serum (Clonetics).
Stable expression of GFP reporter through lentiviral
transduction
A stable MDA-MB-231 breast cancer cell line capable of
constituitive, enhanced GFP expression was generated through
lentiviral transduction. For this, viral particles were produced by
transient calcium phosphate transfection of HEK 293t cells with
the GFP-encoding lentivector, pLVTHm, the envelope vector,
pMD2G, and the packaging vector, psPAX2 (all vectors were
obtained from D Trono, University of Geneva, Switzerland).
Transfected cells were incubated for 48h, after which medium
containing the lentiviral particles was harvested and passed
through a 0.45-mm filter. Viral supernatant was placed directly
on subconfluent MDA-MB-231 cells, which were then incubated
overnight before the cells were washed gently with sterile PBS and
the media was refreshed.
In vitro angiogenesis assay
Tube formation assays were performed using an in vitro
Angiogenesis Assay Kit (Chemicon International, Inc., Temecula,
CA, USA). Briefly, solid gels were prepared according to the manu-
facturer’s instructions on a 96-well tissue culture plate. HUVECs
seeded into 25-cm
2 flasks and grown to confluency of 70–80%,
were irradiated 3h after ADPM06 administration (150nM). Cells
were then trypsinised and seeded at a density of 5 10
4 cells per
well in EGM onto the surface of the solid endothelial cell gel
matrix. The cells were incubated for 7h at 371Ci naC O 2 incubator.
Tube formation was observed under an inverted light microscope
at  20 magnification. Microscopic fields were photographed with
a digital camera. The number of branch-points per field-of-view
was counted, and the length of tubules was quantified using ImageJ
1.41 (National Institutes of Health, Bethesda, MD, USA). Mann–
Whitney U-test was used to compare control and treated samples.
Animal models
All animal experiments were licensed by the Department of Health
and Children, Ireland and specific protocols reviewed by the
Animal Research Sub Committee (ARSC) at University College
Dublin. Imaging protocols were conducted in accordance with the
recommendations of the Canadian Council on Animal Care and of
the in-house Ethics Committee for Animal Experiments at
Universite ´ de Sherbrooke. All studies were in full compliance
with EU guidelines. Female C57/Bl or Balb C nu/nu mice were
received to the SPF-grade Conway Institute Biotechnical Services
(CIBS) Xenograft Facility at 4–6 weeks old (Harlan, UK). Initially,
normal C57/Bl mice were parenterally treated (i.v.) with ADPM06
(1–10mgkg
 1) to establish a basic toxicity profile for the novel
photosensitiser. There was no evidence of either acute or chronic
(6-month follow-up) toxicity. No significant histopathological
changes were observed on veterinary pathologist’s examination
of the liver, kidney, heart, or spleen. Specifically, no necrotic,
degenerative, inflammatory, or hyperplastic processes were
observed (data not shown). For lightþdrug toxicology studies
(as well as drug efficacy studies), C57/Bl mice were shaved on the
right hind limb and depilated with Nair (Carter-Wallace Inc., New
York, NY, USA). Mice were anesthetised with an i.p. injection of
ketamine/xylazine cocktail (90mgkg
 1 ketamine and 10mgkg
 1
xylazine). One million LLC/1 lung carcinoma cells were injected
subcutaneously in one mid-thigh area suspended in 100ml PBS.
Tumours grew predictably in all the mice and reached a size of
5- to 6-mm diameter 5–7 days after injection, at which time they
were used for PDT. Female Balb C nu/nu mice were similarly
anesthetised and five million MDA-MB-231-GFP or MDA-MB-231-
luc cells were injected subcutaneously in 100ml PBS/Matrigel
(50:50) into the right forelimb. Both cell lines similarly
reached 5–6mm in diameter within 7–10 days and were subjected
to PDT as described below. For dynamic PET and MRI studies,
MAT III B tumour cells (obtained from ATCC) were inoculated
intradermally (5 10
6 cells in PBS) into both axillary areas on
rats 6–8 days before the experiment. Rats were fasted 12h before
PDT treatment.
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sDrug efficacy studies: PDT protocol
ADPM06 in PBS/Cremophor solvent was injected at a dose range of
1–10mgkg
 1 in 0.3ml solution through the lateral tail vein. The
PDT was performed immediately after injection using a Lumacare
LC-122M fibre-optic light delivery system (Lumacare, Newport
Beach, CA, USA) emitting light at 690nm (±25nm). The illumi-
nating spot had a diameter of 11mm and was positioned so that
the entire tumour and a surrounding 2–3mm area of normal tissue
were exposed to light with no evident temperature increase at the
site of irradiation. Mice were anesthetised as described above and
the tumour-bearing limb positioned under the spot. Total fluences
between 50 and 200Jcm
 2 were delivered at a fluence rate of
717mWcm
 2. Some mice had LLC/1, MDA-MB-231-luc, or MDA-
MB-231-GFP tumours illuminated without having received an earlier
injection of ADPM06. In addition, another group of animals were
treated with ADPM06 i.v. in the absence of light. At the completion
of illumination, mice were allowed to recover in an animal warmer
until they resumed normal activity. A positive tumour response was
assigned to tumours that appeared macroscopically as flat blackened
eschars and necrotic tissue within a few days after PDT. Animals
were considered cured after complete tumour regression; this was
defined as the absence of a palpable tumour.
Dynamic PET and MRI studies: PDT protocol
Rats bearing 13762 MAT B III tumours were anesthetised and two
cannulas were inserted in the caudal veins, one for radiotracer
infusion or contrast agent injection (MRI) and the other for
photosensitiser administration. The animals were then placed on
the scanner bed equipped with a heat pad and instrumented for life
sign monitoring. For the dynamic PET studies, 0.8mgkg
 1 of the
photosensitiser was administrated to rats lying in the scanner
through a second cannula 30min after the commencement of
18F-FDG infusion. Illumination was provided immediately after the
photosensitiser injection (less than 5min between photosensitiser
injection and tumour illumination). One tumour was illuminated
with a 670-nm light beam delivered through a fibre optic by a diode
laser (model BWF2-692-0.7-100-0.22-SMA; B&W Tek, Inc., Newark,
NJ, USA) and the other tumour was masked and served as control.
The light beam was spread uniformly over the whole tumour area
and maintained for 215s at a fluence rate of 700mWcm
 2 for a
total fluence of 150Jcm
 2, as before. For PET and MRI imaging
studies at specific time points before or after PDT, the photo-
sensitiser administration and tumour illumination were performed
off the scanner after the same treatment protocol as above.
Optical imaging
Optical imaging was performed with an IVIS Spectrum
small-animal in vivo imaging system (Caliper LS), having both
bioluminescence and fluorescence capabilities. Images and mea-
surements of fluorescent signals were acquired and analysed using
Living Image Software v3.0 (Caliper LS). Excitation and emission
wavelengths of 475 and 540nm, respectively, were used for
acquiring in vivo GFP fluorescent images, whereas excitation and
emission wavelengths of 640 and 720nm, respectively, were used
for acquiring in vivo ADPM06 fluorescent images. All images were
attained using a 1-s exposure time and an f/stop of 1, with a
sampling of multiple angles with animal remaining sedated.
For biodistribution studies, mice were injected with 2mgkg
 1
ADPM06 through the tail vein, anesthetised before being imaged
at ADPM06 excitation and emission wavelengths at various time
points. Mice were then euthanized, the tumour, liver, lungs, heart,
spleen and kidneys were extracted, and ex vivo fluorescence
images were acquired. MDA-MB-231-luc tumours were imaged
following i.p. administration of luciferin substrate (150mgkg
 1).
PET imaging
PET imaging was performed with the Sherbrooke avalanche photo-
diode PET scanner (University of Sherbrooke, Quebec, Canada)
(Lecomte et al, 1996), achieving 2.1mm resolution in-plane (14ml
volumetric resolution). The scanner is made of four detector rings
with a total of 512 pixel detectors defining an axial field-of-view of
2.5cm with a diameter up to 10cm. The massively parallel processing
o fp i x e ld e t e c t o r sm a k e si tp o s s i b l et oi m a g eo v e ral a r g er a n g eo f
radioactivity with negligible dead time losses. Therefore, dynamic PET
imaging of tumour
18F-FDG uptake during PDT treatment could be
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Figure 1 In vitro endothelial cell tubule formation assay. (A) The HUVECs, post-treatment with ADMP06-mediated PDT, were seeded in Matrigel-coated
plates and photographed 7h post-seeding. Images shown for PDT treatment (150nM ADPM06þ16Jcm
 2 light) compared with cells alone, light alone, and
drug alone controls. Experiment was carried out in triplicate, with representative images shown. Image analysis determined the total tubule length (B),
and the number of branch-points per junction (C) in each sample. The Mann–Whitney U-test was used to compare control and treated samples.
(ND, non-determinable).
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sperformed with radiotracer infusion for up to 4h, starting at the same
time as the dynamic image acquisition. Rats were typically infused at
0.008mlmin
 1 with an initial
18F-FDG radiotracer concentration of
B1.5mCiml
 1. Tumours were positioned at the centre of the scanner
axial field-of-view in such a way to allow illumination of one tumour
with the laser light during the scan, whereas the other one (used as
control) was masked. Rats were anesthetised using a mix of 2%
isofluorane in oxygen with the flow set at no more than 2mlmin
 1
during these extended scans and the animal vital signs were
monitored and recorded throughout the entire scan time to ensure
a stable physiological status at all times and for later reference.
Scanning was stopped if vital signs were not at physiological status.
The list mode PET data were sorted out into 1-min frames and PET
images were reconstructed using 10 iterations of a maximum
likelihood expectation maximisation (MLEM) algorithm that models
detector response. Image series con s i s t e do fu pt o2 4 01 - m i nf r a m e s .
These PET measurements were performed with PDT treatment
(n¼5), with ADPM06 alone (n¼1) and light alone (n¼1). Regions
of interest (ROIs) were traced over the treated and the control
tumours using the last frame of the dynamic image series and applied
to all frames. Time-activity curves corrected for radioactive decay
were generated from the maximum counts averaged over 4 pixels in
the ROIs. Taking the control tumour as reference, the relative
metabolic activity of the treated and control tumours was estimated as
t h er a t i oo ft h es l o p eo ft h e s et w oc u r v e s .M e a ng r o u pv a l u e sw e r e
tested for statistical significance using a one-way analysis of variance.
The PET images of the tumours after a bolus injection of 1–1.3mCi
18F-FDG (in o1min) were also obtained at specific time points before
PDT and at 30min, 24 and 48h after PDT treatment to monitor
tumour metabolism over a more extended period of time by simply
comparing
18F-FDG uptake values at equilibrium in tumour ROIs. A
static 1-min image frame at 30min after the bolus injection was
extracted from the list mode data and reconstructed using 10 MLEM
iterations. The relative metabolic activity of the treated and control
tumours were also estimated by ROI analysis as described above.
Magnetic resonance imaging
The MRI was performed with a Varian 7T small animal scanner
(Varian Inc., Palo Alto, CA, USA) using a 63-mm volume coil. Rats
were anesthetised using a mix of 2% isofluorane in oxygen with the
flow set at 2mlmin
 1 and were restrained to prevent movement
during the experiment. Dynamic acquisition was started 3, 24, and
48h after PDT (T1-weighted images, repetition time¼210ms, echo
time¼2.49ms, field-of-view 4 5cm
2, matrix¼128 128, flip
angle¼301, four averages, 20 slices of 1.5mm). Sets of images were
acquired continuously. A bolus of 0.6ml gadolinium diethylene-
triamine pentaacetic acid (Gd-DTPA) (Magnevist, Berlex Canada
Inc., Pointe Claire, QC, Canada) was injected i.v. 5min after the
start of the scan (with an infusion rate of 600mlmin
 1) through the
tail vein after the second set of images.
RESULTS
In vitro effects of ADMP06-mediated PDT on HUVECs
The capacity of HUVECs to form new tubules in Matrigel
(BD Biosciences, Bedford, MA, USA) was directly inhibited after
PDT with ADPM06 (Figure 1), indicative of an anti-angiogenic
effect. No effects on tubule length (Figure 1B) or branch-point
formation (Figure 1C) were seen on cells either irradiated with
light alone, or treated with drug alone.
In vivo response to ADPM06-mediated PDT delivered with
short (immediate) drug–light interval
LLC/1 tumour-bearing mice were used to determine drug–light
combination tolerance. Initial studies comparing toxicity profiles
of ADPM06 in combination with light (70–300Jcm
 2) provided
early evidence of tumour response (Figure 2A). Mass tumour
necrosis was evident within 72–96h and an optimal light fluence
of 150Jcm
 2 was determined. After PDT, oedema and inflamma-
tion became apparent by 1–2 days, with the subsequent develop-
ment of necrosis and eschar by days 3–5, but confined to the
tumour region. Oedema that healed within a few days leaving no
tissue damage was observed in the illuminated normal tissue
around the tumour. Some erythema (that cleared within the same
time) in the immediately adjacent, non-illuminated, normal tissue
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Figure 2 In vivo response to ADPM-mediated PDT delivered with short
drug–light interval. (A) Photographs of LLC/1 syngeneic murine tumour
model before, 48 and 96h after treatment (2mgkg
 1 AD-
PM06þ150Jcm
 2 light). (B) and (C) MDA-MB-231-GFP xenograft
tumour ablation after treatment (2mgkg
 1 ADPM06þ150Jcm
 2 light)
as shown by reduction in measurable tumour fluorescence. Representative
images of a single animal from four repeat studies. Decreasing fluorescence
intensity values are shown (photons per second per cm
2 per steradian).
(D) ADPM06 efficacy study in MDA-MB-231-GFP xenograft model.
Treatment groups were as follows: PDT group (2mgkg
 1 ADPM06
IVþ150Jcm
 2 light (n¼7)), light-alone group (150Jcm
 2 (n¼8)), drug-
alone group (2mgkg
 1 ADPM06 i.v. (n¼14)), and vehicle control (n¼9).
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swas invariably observed. In contrast, tumour healing took approxi-
mately 20–30 days. The skin covering the tumour was initially
damaged, but underwent remodelling during the healing process.
For xenograft studies, MDA-MB-231-GFP cells inoculated
subcutaneously into nude mice developed tumours. Within 7–10
days, when the tumours reached a diameter of about 7–9mm, PDT
treatment was performed, using different light–drug concentra-
tions. In all cases, tumours were irradiated immediately after i.v.
drug delivery. The illumination of the tumour always included
2–3mm of surrounding normal tissue. Tumour ablation over
time, as shown by reduction in GFP fluorescence, is shown in
Figure 2B and C. All animals at drug–light doses of 2mgkg
 1
ADPM06þ100–200J/cm
2 light responded to therapy. Cure was
defined as the disappearance of tumour with no recurrence at 6
months. All animals tolerated 2mgkg
 1 ADPM06þ150J/cm
2 light
well, resulting in a high tumour cure rate of 71%. In total, 45% of
animals treated with 2mgkg
 1 ADPM06þ100Jcm
 2 light were
cured, 33% with 2mgkg
 1 ADPM06þ50Jcm
 2 light and 27%
with 1mgkg
 1 ADPM06þ100J/cm
2 light. A typical growth
curve showing controls vs treated animals (2mgkg
 1 AD-
PM06þ150Jcm
 2 light) is shown in Figure 2D.
Drug biodistribution and clearance as determined by
optical imaging
Ex vivo imaging and fluorescence quantification from excised
organs was performed to establish drug biodistribution patterns
(Figure 3A). A peak in fluorescence intensity was observed in the
lungs, liver, kidneys, heart, spleen, and tumour within 1h of drug
administration (Figure 3B). Fluorescence within these organs
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Figure 3 In vivo biodistribution of ADPM06 as measured by optical imaging. (A) Representative images of excised organs from Balb/C nude mice bearing
subcutaneous MDA-MB-231-luc tumours. Mice were killed over a 48-h interval after i.v. injection of ADPM06 (2mgkg
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by 24h and seems to be cleared from the animal by 48h. MDA-MB-231-luc tumour model used in biodistribution studies to prevent GFP autofluorescence
into the NIR channel. (B) Quantification of fluorescence intensity from the lungs, heart, spleen, tumour, kidneys, and liver over 48h (photons per second per
cm
2 per steradian). (C) In vivo fluorescence imaging of Balb C nude mice bearing subcutaneous MDA-MB-231-luc tumours before and after i.v. injection of
ADPM06 (2mgkg
 1). Animal shown before administration of ADPM06, 15min post-injection and 24h post-injection. Fluorescence intensity of ADPM06-
treated animals (photons per second per cm
2 per steradian) was normalised to background fluorescence of animals before ADPM06 administration.
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completely cleared from the system by 48h. Measurable tumour
fluorescence decreases at a slower rate compared with the lungs,
liver, and kidneys. Comparison of whole body fluorescence
associated with ADPM06, 15min and 24h post-injection illustrated
negligible retention of ADPM06 in the skin (Figure 3C). Critically,
drug-associated fluorescence was below system threshold 48h after
parenteral injection.
PET-based evaluation of ADPM06 effects in vivo
Rats bearing 13762 MAT B III tumours receiving ADPM06-
mediated PDT were assessed by dynamic PET to investigate the
mechanistic basis of this treatment in vivo (Figure 4A). Time-
activity curves showed a decline in
18F-FDG uptake rate in the
treated tumour relative to control tumour after light treatment.
Photosensitiser and light controls showed no significant modifica-
tion of the
18F-FDG uptake rate relative to the control (untreated)
tumour in PDT-treated rats, confirming the absence of any
detectable metabolic effects due to ADPM06 or light alone.
Therefore, transient changes in the
18F-FDG uptake rate, which
occurred from 10 to 30min after the commencement of illumina-
tion can clearly be related to the effect of PDT. The subsequent
slope change of the
18F-FDG uptake curve observed 430min after
PDT is likely the result of the time-confined, short PDT insult
causing a partial, but permanent, drop in tumour metabolic
activity, specifically 50% (mean±7% Po0.05; n¼5) from the
slope value (counts per pixel per minute) of the
18F-FDG uptake
curves after PDT. Such behaviour does not suggest extensive
cellular damage during this observation time window and is
consistent with a vascular-targeting response depriving tumour
cells of blood supply, when light irradiation is performed
immediately after photosensitiser delivery. Bolus tracer injection
confirmed reduced tumour metabolism at 30min post PDT and
almost complete suppression of tumour metabolic activity at
24 and 48h post PDT (Figure 4B and Table 1), which is also
consistent with delayed cell death resulting from vascular stasis.
MRI perfusion studies with ADPM06-mediated PDT
The MRI was employed to further assess effects of ADPM06-
induced PDT on tumour vascular perfusion. Immediately after
dynamic PET acquisition (B3h post treatment) as described
above, 0.6ml of MRI contrast agent (Gd-DTPA) was injected i.v. at
0.6mlmin
 1 and MRI scans were performed at B3, 24, and 48h
after treatment. The evident difference in accumulation of contrast
agent between control and PDT-treated tumours is indicative of an
overall decrease in vascular perfusion, as well as a decrease in
perfusion over time. These data are also consistent with a vascular-
targeting effect following immediate light irradiation after i.v.
administration of the photosensitiser (Figure 5).
DISCUSSION
Our previous studies have shown the ADPM family of photo-
sensitisers to be an exciting new class of agents having significant
potential for preclinical development (Gorman et al, 2004;
Gallagher et al, 2005). Unlike many other PDT photosensitisers,
ADPM agents are synthetic and can be readily modified about the
core periphery to affect drug properties (McDonnell et al, 2005). In
this study, we have shown our lead agent, ADPM06, to be well
tolerated and highly efficacious in vivo, when a short drug–light
interval protocol was used. Moreover, we have also shown a
classical PDT-associated light and photosensitiser dose-dependent
response in terms of efficacy, as well as evidence of anti-angiogenic
effects in vitro. The observed cure rates (470%) in a xeno-
graft model of breast cancer are encouraging and comparable
with the leading vascular-targeting PDT agents currently in clinical
development (Trachtenberg et al, 2007, 2008). Similar thera-
peutic responses to treatment were also observed in the LLC/1
Lewis lung carcinoma and 13762 MAT B III breast cancer rodent
models.
We have also shown that ADPM06 has an organ biodistribution/
clearance pattern consistent with that of an ideal photosensitiser
(Chen et al, 2006). Using the innate fluorescence properties of
ADPM06, its biodistribution pattern in major organs after
parenteral delivery has been established. Drug-related fluorescence
was undetectable from all organs within 48h after treatment. There
was no apparent toxicity associated with any of the major organs
after examination by a veterinary pathologist, indicating no
adverse effects of treatment. Importantly, we were unable to detect
significant accumulation of drug in the skin of animals 24h after
i.v. delivery of drug, suggesting that patients receiving ADPM06
would be unlikely to suffer the effects of unwanted photosensitiser-
induced skin photosensitisation.
Pre-i.v. 15 min post i.v. 24 h post i.v.
Color scale
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Max = 3.75e8
1.5
2.0
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×
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8
Figure 3 Continued
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sDynamic PET has been previously used to investigate photo-
sensitiser in vivo mechanism of action (Lapointe et al, 1999; Berard
et al, 2006a, 2006b). Accordingly, this technology was exploited to
investigate the mechanism of action of ADPM06. Dynamic PET
profiles, which measure the transient metabolic status of the
tumour, provided some initial evidence towards a probable
vascular-targeting response after PDT with ADPM06, when a short
drug–light interval treatment regimen was used. As rapid
destruction of tumour tissue after ADMP06-mediated PDT makes
histological assessment of vascular effects difficult, we sought to
further examine vascular perfusion effects using MRI. This
imaging modality has previously been successfully used to
investigate photosensitiser vascular-targeting mechanism of action
both in the experimental (Gross et al, 2003; Huang et al, 2006) and
in the clinical context (Haider et al, 2007). Our data indicate that
vascular perfusion is significantly decreased within 3h after
ADPM06-induced treatment. This effect is escalated over time
and is consistent with a vascular-targeting effect when light
activation is performed whilst photosensitiser is contained within
the vasculature. Direct assessment of the vascular status with MRI
also provides crucial information for the interpretation of PET
data. Indeed, the PDT vascular shutdown confirmed by MRI
essentially discards direct cellular effects as the cause of the
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Figure 4 The PET approach to assessing vascular-targeting effect in vivo. (A) Time-activity curves during
18FDG infusion representing dynamic radiotracer
uptake in intradermal implanted 13762 MAT B III tumours in PDT (0.8mgkg
 1 ADPM06þ150Jcm
 2 light), light alone (150Jcm
 2), and ADMP06 alone
(0.8mgkg
 1) treated animals. The delay between ADPM06 injection and illumination commencement was o5min.
18F-FDG PET image slices through
tumours taken at selected time points before and after treatment are also shown. (B) The PET image slices of tumours after bolus injection of 1–1.3 mCi
18FDG and 30min uptake at selected time points before and after ADPM06-mediated PDT, illustrating the change in tumour metabolic activity. White
arrows, control tumour; grey arrows, treated tumours.
Table 1 Relative uptake of
18F-FDG within treated vs control tumours
over time
Time
18F-FDG relative uptake
Pre-PDT 1.15
30min 0.65
24h 0.33
48h 0.20
Abbreviation: PDT¼photodynamic therapy.
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blood oxygen level-dependent functional MRI has been applied to
further probe PDT mechanism of action in the in vivo setting and,
most importantly, to determine vascular-targeting effects after
treatment (Seshadri et al, 2008).
When compared with the historical gold-standard, that is,
clinical PDT protocols that allow tumour cell accumulation of
photosensitiser before light activation, it has been proposed that
the anti-vascular strategy comprises the following benefits: First,
blood oxygen levels are known to be the highest at the vascular site
in comparison to surrounding tissues, and sensitiser levels in the
blood are maximal shortly after injection – an optimal situation for
successful PDT. Second, the vascular endothelial cells are directly
accessible to the blood-borne sensitiser molecules. Third, it is
likely that vascular rupture and haemorrhage formation facilitate
rapid discharge of the sensitiser molecules into the tumour site
more efficiently than expected by passive diffusion across capillary
walls (Chen et al, 2006). Tumour cell killing is achieved by
oxidative insult during illumination and indirectly by subsequent
oxygen and nutrient deprivation due to blood stasis resulting in
hypoxia, necrosis, and tumour eradication (Chen et al, 2006).
These factors are proposed to synergistically contribute to the high
success rate of the vascular-targeting treatment protocol.
In summary, we have shown that our lead novel photo-
sensitiser, ADPM06, elicits an impressive therapeutic response in
tumour models and is well tolerated in vivo. The drug quickly
clears both from the skin and internal organs as shown by
optical imaging. Application of a combined PET/MRI approach
provided evidence for a vascular-targeting response to therapy
with this agent. Both imaging modalities may be further used
during clinical evaluation as useful biomarkers of therapeutic
response. Taken together, the preclinical data set presented here
clearly establishes lead BF2-azadipyrromethene ADMP06 as an
exciting new photosensitiser for potential application in a Phase 1
clinical trial.
ACKNOWLEDGEMENTS
Funding is acknowledged from the Science Foundation Ireland, the
Health Research Board of Ireland, and University College Dublin.
The UCD Conway Institute is funded by the Programme for Third
Level Institutions (PRTLI), as administered by the Higher
Education Authority (HEA) of Ireland. We thank Me ´lanie
Archambault, Luc Tremblay, and Martin Lepage of Universite ´ de
Sherbrooke for their assistance with MRI studies.
REFERENCES
Berard V, Lecomte R, van Lier JE (2006a) Positron emission tomography
imaging of tumor response after photodynamic therapy. J Environ Pathol
Toxicol Oncol 25: 239–249
Berard V, Rousseau JA, Cadorette J, Hubert L, Bentourkia M,
van Lier JE, Lecomte R (2006b) Dynamic imaging of transient metabolic
processes by small-animal PET for the evaluation of photosensitizers in
photodynamic therapy of cancer. J Nucl Med 47: 1119–1126
Chen B, Pogue BW, Hoopes PJ, Hasan T (2006) Vascular and cellular
targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 16:
279–305
Gallagher WM, Allen LT, O’Shea C, Kenna T, Hall M, Gorman A, Killoran J,
O’Shea DF (2005) A potent nonporphyrin class of photodynamic
therapeutic agent: cellular localisation, cytotoxic potential and influence
of hypoxia. Br J Cancer 92: 1702–1710
Gorman A, Killoran J, O’Shea C, Kenna T, Gallagher WM, O’Shea DF (2004)
In vitro demonstration of the heavy-atom effect for photodynamic
therapy. J Am Chem Soc 126: 10619–10631
Gross S, Gilead A, Scherz A, Neeman M, Salomon Y (2003) Monitoring
photodynamic therapy of solid tumors online by BOLD-contrast MRI.
Nat Med 9: 1327–1331
Haider MA, Davidson SR, Kale AV, Weersink RA, Evans AJ, Toi A,
Gertner MR, Bogaards A, Wilson BC, Chin JL, Elhilali M, Trachtenberg J
(2007) Prostate gland: MR imaging appearance after vascular targeted
photodynamic therapy with palladium-bacteriopheophorbide. Radiology
244: 196–204
Hamblin MR, Hasan T (2004) Photodynamic therapy: a new antimicrobial
approach to infectious disease? Photochem Photobiol Sci 3: 436–450
Huang Z, Haider MA, Kraft S, Chen Q, Blanc D, Wilson BC, Hetzel FW
(2006) Magnetic resonance imaging correlated with the histopatho-
logical effect of Pd-bacteriopheophorbide (Tookad) photodynamic
therapy on the normal canine prostate gland. Lasers Surg Med 38:
672–681
Kossodo S, LaMuraglia GM (2001) Clinical potential of photodynamic
therapy in cardiovascular disorders. Am J Cardiovasc Drugs 1: 15–21
Lapointe D, Brasseur N, Cadorette J, La Madeleine C, Rodrigue S, van Lier
JE, Lecomte R (1999) High-resolution PET imaging for in vivo
monitoring of tumor response after photodynamic therapy in mice.
J Nucl Med 40: 876–882
Lecomte R, Cadorette J, Rodrigue S, Lapointe D, Rouleau D, Bentourkia M,
Yao R, Msaki P (1996) Initial results from the Sherbrooke avalanche
photodiode positron tomography. IEEE Trans Nucl Sci 43: 1952–1957
McDonnell SO, Hall MJ, Allen LT, Byrne A, Gallagher WM, O’Shea DF
(2005) Supramolecular photonic therapeutic agents. J Am Chem Soc 127:
16360–16361
Palumbo G (2007) Photodynamic therapy and cancer: a brief sightseeing
tour. Expert Opin Drug Deliv 4: 131–148
Control
tumour Treated   
tumour
3 h post PDT 24 h post PDT  48 h post PDT
Figure 5 MRI approach to assessing vascular-targeting effect in vivo. The MRI of control 13762 MAT B III rat tumour (white circle) and PDT-treated
tumour (0.8mgkg
 1 ADPM06þ150Jcm
 2 light) (dashed white circle) at B3, 24, and 48h post-treatment with a Gd-DTPA injection, illustrating the
change in tumour perfusion.
Studies of novel photosensitisers by multi-modality imaging
AT Byrne et al
1572
British Journal of Cancer (2009) 101(9), 1565–1573 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sSchmidt-Erfurth U, Sacu S (2008) Early Retreatment Study Group.
Randomized multicenter trial of more intense and standard early
verteporfin treatment of neovascular age-related macular degeneration.
Ophthalmology 115: 134–140
Seshadri M, Bellnier DA, Vaughan LA, Spernyak JA, Mazurchuk R, Foster
TH, Henderson BW (2008) Light delivery over extended time periods
enhances the effectiveness of photodynamic therapy. Clin Cancer Res 14:
2796–2805
Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey
SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson
BC, Elhilali M (2007) Vascular targeted photodynamic therapy with
palladium-bacteriopheophorbide photosensitizer for recurrent prostate
cancer following definitive radiation therapy: assessment of safety and
treatment response. J Urol 178: 1974–1979
Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A,
Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M
(2008) Vascular-targeted photodynamic therapy (padoporfin, WST09)
for recurrent prostate cancer after failure of external beam radiotherapy:
a study of escalating light doses. BJU Int 102: 556–562
Triesscheijn M, Baas P, Schellens JH, Stewart FA (2006) Photodynamic
therapy in oncology. Oncologist 11: 1034–1044
Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy
for neovascular age-related macular degeneration. Cochrane Database
Syst Rev CD002030
Studies of novel photosensitisers by multi-modality imaging
AT Byrne et al
1573
British Journal of Cancer (2009) 101(9), 1565–1573 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s